Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

In a groundbreaking collaboration poised to redefine the landscape of genomics and precision health, MGI Tech has joined forces with Eurofins Genomics Europe Genotyping A/S, marking a pivotal moment in the advancement of large-scale genomic projects. This partnership heralds the first corporate order of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in Europe, alongside the cutting-edge ZTRON Appliance data center and an array of sophisticated laboratory automation products and systems from MGI.

A Leap Forward in Genomic Sequencing

The T20 sequencer, powered by MGI's proprietary DNBSEQ™ technology, stands as a beacon of innovation in genetic sequencing. By dramatically reducing sequencing costs to under $100 per genome for annual runs of 50,000 Whole Genome Sequences (WGS), the T20 has captured the attention of the global scientific community. Designed to tackle the most demanding sequencing challenges, the T20 meets a broad spectrum of high-throughput sequencing requirements essential for scientific and clinical research, including WGS, Whole Genome Bisulfite Sequencing (WGBS), single long fragment read (stLFR), single-cell sequencing, Stereo-seq, and more.

Since its launch in February 2023, the T20 has been rapidly adopted by leading research institutions and healthcare providers worldwide, showcasing its versatility and efficiency in driving forward genomic studies and applications.

The Power of Collaboration

Eurofins Genomics, a subsidiary of the Eurofins Scientific Group, has been at the forefront of genomic analysis since 1990. With laboratories spread across more than 50 countries and a team of over 55,000 employees, Eurofins Genomics has emerged as a key player in the realm of specialty esoteric and molecular clinical diagnostic testing in Europe and the United States. Offering a comprehensive portfolio of over 200,000 analytical methods, Eurofins Genomics excels in assessing the safety, identity, composition, authenticity, origin, and purity of biological substances and products, alongside pioneering clinical diagnostics.

This strategic partnership between MGI and Eurofins Genomics combines their respective expertise and resources, setting the stage for significant strides in genomics research and clinical applications. Together, they aim to catalyze the development of personalized medicine and enhance healthcare outcomes on a global scale.

A Vision for the Future

"We are thrilled to work with Eurofins Genomics to leverage the T20's ultra-high throughput and remarkable cost-efficiency, empowering large population genome projects across the world," stated Dr. Yong Hou, General Manager of MGI Europe and Africa. "With this partnership, we hope to improve the accessibility of cost-effective sequencing to researchers globally."

As MGI Tech and Eurofins Genomics embark on this exciting journey, their collaboration promises to unlock new possibilities in the realms of sequencing, genotyping, and genomics, driving the evolution of precision health and personalized medicine for years to come.

*For Research Use Only. Not for use in diagnostic procedures.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.